List view / Grid view
Vanitha Margan, Global Product Manager for Bio-Plex Multiplex Immunoassays at Bio-Rad Laboratories, reveals how multiplexing is being used to realise the full potential of extracellular vesicles in disease monitoring.
Japanese researchers have designed a pure capped mRNA vaccine which has shown a better protein production in the immune system.
In this article, Dr Vincent Blomen, Senior Director of Target Discovery at Scenic Biotech, takes us through the realm of rare diseases. In the case of most of these diseases, a singular genetic anomaly often reigns supreme, yet its impact on patients can be vastly divergent. Enter modifier genes, the…
Single-cell transcriptomic RNA sequencing analysis has allowed US researchers to identify the specific populations and the dynamic transition states during senescence initiation and progression.
Conditions like chronic inflammation, muscle loss and bone loss have an elevated microRNA, US researchers attempted to block this in aged mice.
UCLA have developed technology using nanoparticles that deliver mRNA to liver cells, that could provide a platform to fight allergies.
US scientists have developed new mRNA vaccines for Zika virus and HIV-1 that produce a strong mother-to-child transmission of antibodies, in rabbits.
In this ebook are articles on the future potential for mRNA therapies and combatting new variants of the SARS-CoV-2.
Japanese researchers combine cutting edge mass spectrometry with software analysis to elucidate mRNA structure.
Researchers have presented comprehensive multi-omic profiles to identify genes, non-coding RNAs, proteins, and plasma metabolites involved in NAFLD-to-NASH progression.
Researchers have developed a computational DNA droplet with the ability to recognise specific combinations of chemically synthesised microRNAs that act as biomarkers of tumours.
By inhibiting the activity of microRNA-194 (miR-194), scientists prevented prostate cancer cells from developing treatment resistance in vitro.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
A team has found that a mutation in the ATAXIN-1 gene causes spinocerebellar ataxia type 1 (SCA1), presenting a drug target for the condition.
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
